Pharmacology’s Anthony Berdis discusses leukemia breakthroughs

Leukemia studies show promise for less-toxic, more-effective treatment

The Plain Dealer: School of Medicine researchers have developed an agent that selectively kills leukemia cells that produce too much of an enzyme called terminal deoxynucleotidyl transferase. “Most therapeutic agents today are not selective,” said Anthony Berdis, assistant professor of pharmacology. “They damage the immune system.”